Award Number: DAMD17-03-1-0298

TITLE: Improving Symptom Control, QOL, and Quality of Care for Women with Breast Cancer: Developing a Research Program on Neurological Effects Via Doctoral Education

PRINCIPAL INVESTIGATOR: Marie Bakitas
Tim A. Ahles, Ph.D.

CONTRACTING ORGANIZATION: Dartmouth College
Hanover, New Hampshire 03755-1404

REPORT DATE: May 2005

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**Title and Subtitle:**
Improving Symptom Control, QOL, and Quality of Care for Women with Breast Cancer: Developing a Research Program on Neurological Effects Via Doctoral Education

**Authors:**
Marie Bakitas
Tim A. Ahles, Ph.D.

**Performing Organization:**
Dartmouth College
Hanover, New Hampshire 03755-1404

**E-mail:** Marie.bakitas@dartmouth.edu

**Sponsoring Agency:**
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

**Distributions Statement:**
Approved for Public Release; Distribution Unlimited

**Abstract:**
The purpose of this traineeship is to develop the academic and research skills of an expert advanced practice nurse towards achieving the career goal of becoming a Clinical Breast Cancer Research Scientist. In conjunction with the doctoral program, through a mentored research experience Ms. Bakitas is expanding an established research program on CNS effects of breast cancer treatment by developing a parallel focus on the peripheral nervous system effects of chemotherapy, (Chemotherapy-Induced Peripheral Neuropathy [CIPN]), on quality of life. The major achievements of the trainee at this annual report are successful accomplishment of the planned training activities/tasks originally outlined for the second year, with an additional achievement of ongoing participation as a consultant in a funded neuropathic pain grant, abstract presentations, acceptance of doctoral proposal and acquiring an ACS doctoral scholarship. The significance of these achievements is that the training has provided for ongoing development of a clinical nurse expert towards development of a program of breast cancer research.

**Subject Terms:**
Cancer control, outcomes research, quality of life, symptom management, neurological effects, doctoral education

**Security Classification:**
Unclassified

**Number of Pages:**
37

**Price Code:**
Unclassified

NSN 7540-01280-5500
Table of Contents

Cover............................................................................................................................

SF 298............................................................................................................................

Table of Contents........................................................................................................

Introduction..............................................................................................................1

Body.............................................................................................................................1

Key Research Accomplishments..............................................................................3

Reportable Outcomes...............................................................................................4

Conclusions................................................................................................................4

References..................................................................................................................4

Appendices................................................................................................................5

A. Statement of Work
   Revised Statement of Work
B. Poster Abstract Presented at the 7th International Conference on Neuropathic Pain,
   Bermuda (11/04), at the 8th National Conference on Cancer Nursing Research, Ft.
   Lauderdale, FL and at the 19th Annual Neuroscience Day, DHMC, (2/05)
C. Transcript
D. Conceptual Model of Trajectory of Neurological Effects
E. Conceptual Model of CIPN Effects on QOL
F. Updated Literature Review for Dissertation Proposal
**Introduction**

This is the second year of a training grant that proposed an interdisciplinary, mentored, clinical research experience on the understudied area of neurological effects of breast cancer treatment through a doctoral training program. A no cost extension was granted thus extending the grant period to 14 May 06 (Months 25-36). Hence this annual report will summarize the accomplishments of Months 13-24 and will describe the anticipated work of the extension period (Months 25-36). A revised Statement of Work (revisions appear in bold) reflects the activities of the extension and has been modified slightly based on findings from the previous year’s work (described below). The revised statement has been submitted (4/20/05) for approval to Ms. Kimbark and is included (in addition to the original statement of work) as Appendix A.

The purpose of this traineeship is to develop the academic and research skills of the trainee within the context of a doctoral nursing program and the mentor’s funded program of research on (central nervous system) Cognitive Effects of Chemotherapy. The traineeship supports Ms. Bakitas in the long term career goal of developing as a Clinical Breast Cancer Research Scientist. Ms. Bakitas is expanding the Center for Psycho-oncology Program’s focus on Central Nervous System/Cognitive Effects of Chemotherapy, by developing an independent, but related focus on the peripheral nervous system effects of chemotherapy (Chemotherapy-Induced Peripheral Neuropathy [CIPN]) on quality of life. Ms. Bakitas has made significant progress in accomplishing tasks described in the original statement of work. As a result of the findings from the first year and the approved dissertation proposal, the Statement of Work has been revised to focus on the understanding the symptom experience and quality of life effects from the perspective of the patient; a specific gap revealed through the past year’s review of literature.

The traineeship continues to be based at two campuses: the Dartmouth Medical School/Norris Cotton Cancer Center, Lebanon, NH and Yale University, New Haven, CT. The trainee’s research mentor, Tim Ahles, PhD, Director of Psycho-oncology Research, Norris Cotton Cancer Center supervises the trainee’s clinical research skill development at Dartmouth. Professor Ruth McCorkle, PhD and dissertation chair, Tish Knobf, RN, PhD supervise the academic and research components at Yale University.

**Body**

This section is organized according to the Tasks listed in the revised Statement of Work (Appendix A). Achievements are reviewed and summarized for each of the original three tasks.

**Task 1. Develop research skills and abilities, including measurement, data analysis, and conceptual model development in breast cancer research through mentorship and doctoral education. (Months 1-18)**

The trainee successfully completed all of the proposed tasks according to the timeline. This was summarized in the accepted 03-04 report Tasks 1.a and 1.b are ongoing throughout the grant period. Tasks 1.f was completed in Dec. 04 when the trainee successfully defended her proposal and passed the Qualifying Exam. Task 1.g, study initiation occurred as of 1 April 05 with scientific review and IRB approval of the study. Task 1. h Dissertation advisement commenced in Summer 04 (see Transcript --Appendix
C) and will continue until successful defense of the dissertation, currently planned for April 06.

Task 2. Collect pilot data on chemotherapy-induced peripheral neurological (CIPN) effects in conjunction with serial neuropsychological and quality of life measures in women enrolled in a longitudinal study of cognitive effects of breast cancer treatment (Months 1-24; extension Months 25-36).

The trainee proposed a series of steps to understand the foundational theoretical, instrumental, and clinical skills necessary to perform appropriate assessment of chemotherapy-induced peripheral neuropathy (CIPN). A major finding from the empirical literature review Task 3a. (Bakitas, Smith, Cohen, & Fadul, 2004) (see Abstract—Appendix B) and consultation with neurological experts demonstrated a lack of consensus or gold standard in physical assessment and self-reported CIPN and quality of life. The multidisciplinary expert panel/project team composed of Dartmouth consultants (Cohen/Fadul/Smith) considered proposing a pilot study to validate a neuropathy tool modified for use in CIPN (the “reduced” Total Neuropathy Score (TNS) (Cavaletti et al., 2003; Chaudhry, Chaudhry, Crawford, Simmons-O’Brien, & Griffin, 2003). However, further study revealed basic flaws in the ability of this new tool to elicit a patient-based understanding of symptoms and quality of life information. Therefore, the trainee has focused the dissertation proposal on addressing this gap in our current understanding of chemotherapy-induced neuropathy. (See further development of this under Task 3).

Per Task 2.c, the FACT-TAXANE was added to the serial measures conducted in two of the mentor’s breast cancer studies: (Ahles) A Prospective, Longitudinal Study of the Cognitive Effects of Chemotherapy, and (Ahles/Saykin): Neural Mechanisms of Chemotherapy-Induced Cognitive Disorder. Recruitment is complete on the former study; data will be available on 67 breast cancer patients who have completed baseline, 1 month, 12 month, and 24 month questionnaires. The latter study is in an early stage and recruitment of 50 women receiving chemotherapy is planned. Preliminary analyses of the neurotoxicity data from the FACT is planned during the extension year. A very preliminary review of some completed questionnaires indicates less indication of neurotoxicity as rated in the questionnaire than is apparent in medical record review of these same women. Such discrepancy is what the current study will attempt to address.

Task 3. Identify gaps in knowledge, research hypotheses, and feasible methods to study and develop interventions as a basis for a doctoral dissertation and future program of research (Months 6-24; extension Months 25-36).

The trainee has been extremely productive in this area. The ongoing literature review (updated citations compiled in Appendix F) in conjunction with the Instrument Development Workshop and dissertation advisement provided the scientific basis for continuing development of the conceptual models, dissertation proposal and other activities related to the study of CIPN. The models (included in Appendix D and E) were reviewed and critiqued by the expert panel (Fadul/Cohen/DeLeo) and will next undergo modification based on empirical data from the dissertation.

A variety of activities occurred in relation to Task 3. f:

(1) The trainee attended three conferences in the preceding year that contributed to knowledge, research networking and dissertation proposal development: 1). July 19-
24- University of North Carolina-"Instrument Development"; 2). International Association for the Study of Pain (IASP) Special Interest Group on Pain Conference “Mechanisms and Treatment of Neuropathic Pain” November 4-6, 2004; and 3). 8th National Conference on Cancer Nursing Research, February 3-5, 2005. An abstract representing the trainee’s review of 45 cancer chemotherapy trials (1980-2004) that measured and reported CIPN was developed and submitted to the latter two conferences as well as locally at the 19th Annual Neuroscience Day at Dartmouth Medical School. The abstract was accepted for poster presentation at each forum, and received a 2nd place award at the Cancer Nursing Research Conference in the “Doctoral Student” division.

(2) As a consultant of the ONS Neuropathic Pain Outcomes Grant (described last report) the candidate has prepared and presented a lecture and training session for nurse practitioners to improve their assessment and examination skills in neuropathy and neuropathic pain. This is available on the Norris Cotton Cancer Center website. A related presentation, co-presented with expert, Joyce Deleo, PhD was published in January 2005 in CD Rom format for “Nurses-Digest Medical-Surgical Nursing”.

(3) As a result of research conferences networking on the topic of CIPN two additional activities have occurred: Ms. Bakitas was asked to prepare a summary of “Neurological Effects of Cancer Treatment” for the Oncology Nursing Society Research Agenda (2005-2007); and she also reviewed an evidence-based guideline on chemotherapy-induced peripheral neuropathy to be published on-line on the ONS site.

Task 3.g was completed (passing of Qualifying Exam) with successful preparation and defense of the dissertation proposal in Dec 04. The purpose of this exploratory, descriptive study is to explore, understand and describe the symptoms and quality of life issues that result from neurotoxic chemotherapy agents’ effect on the peripheral nervous system. Patients’ descriptions through open-ended, semi-structured interview will be the primary means used to understand the experience of living with CIPN (See Appendix G- Study Brochure).

The primary specific aims of the study are to:
1). Describe the CIPN symptom experience from the patient’s perspective;
2). Explore and describe the patient’s experience of living with CIPN.
This investigation will contribute to understanding and likely measurement/instrument refinement and/or development.

Key Research Accomplishments
- Completed doctoral coursework
- Passed Qualifying Examination
- Dissertation proposal completed, accepted by doctoral dissertation committee
- Dissertation proposal approved by Yale University and Dartmouth-Hitchcock Scientific Review and Human Subjects committees
- Dissertation study underway-April 2005
- Continued consultant role on funded research project on CIPN
- Synthesized and Presented CIPN literature for dissertation proposal, 3 accepted poster abstracts, and a manuscript in progress.
• Compiled and Presented “Neurological Effects of Cancer Treatment” Oncology Nursing Society Research Agenda (2005-2007)-To be published 5/05.
• Reviewer for “Chemotherapy-Induced Peripheral Neuropathy” an Oncology Nursing Society on-line evidence based guideline.
• Achieved American Cancer Society Doctoral Dissertation Scholarship (funding available 9/05-9/06)

Reportable Outcomes
The trainee has continued to participate as a consultant on a Neuropathic Pain funded research grant, and has contributed to national organizations CIPN-related science via serving as a contributor on Neurological Effects portion of the 05-07 ONS research agenda and as a reviewer of a soon to be released evidence-based guideline on CIPN. Poster abstracts, describing the foundational work of the dissertation related to measurement issue of CIPN, were accepted for presentation at international, national, and regional scientific meetings. A manuscript describing this in-depth analysis is being prepared for a peer-reviewed multidisciplinary journal. Lastly, the trainee has received notice of qualification for an American Cancer Society Doctoral Scholarship.

Conclusions
Through this training grant Ms. Bakitas has developed an independent doctoral dissertation proposal that is now underway in an understudied area of breast cancer research, namely chemotherapy-induced peripheral neuropathy. This study examines the patient’s symptom experience of CIPN and its impact on quality of life. This research will contribute to an understanding of this dose-limiting effect that can significantly interfere with cancer treatment and quality of life. Furthermore, through this mentored, research training program, the trainee has made significant progress in developing a future career in clinical breast cancer research. This information will be presented this June at the Era of Hope Conference.

References
Appendices

A. Statement of Work
   Revised Statement of Work

B. Poster Abstract Presented at the 7th International Conference on Neuropathic Pain, Bermuda (11/04), at the 8th National Conference on Cancer Nursing Research, Ft. Lauderdale, FL and at the 19th Annual Neuroscience Day, DHMC, (2/05)

C. Transcript

D. Conceptual Model of Trajectory of Neurological Effects

E. Conceptual Model of CIPN Effects on QOL

F. Updated Literature Review for Dissertation Proposal

G. Recruitment Brochure for CIPN study
Statement of Work

This statement of work provides an overview of a two year project in which the candidate will spend half of her week on the Yale Campus and half on the Dartmouth Campus.

Task 1. Develop research skills and abilities, including measurement, data analysis, and conceptual model development in breast cancer research through mentorship and doctoral education. (Months 1-18)
   1. Weekly meeting with Dr. Ahles for mentored research supervision (Months 1-24)
   2. Participate in 15 hrs/wk supervised Research Activities with doctoral faculty (Month 1-18)
   3. Complete Year 1-Spring term (Months 1-5) and Year 2 –Fall and Spring (Months 9-17) required doctoral coursework (Yale)
   4. Take Research Methods (CECS), Neurology, or Pharmacology Cognates (DMS) (Months 1-5, 9-12, 13-17)
   5. Complete Preliminary Exam (at completion of 1st year of coursework) Month 6
   6. Complete Qualifying Exam (at completion of 2nd year of coursework) Month 18
   7. Dissertation underway (Month 21-completion)
   8. Dissertation advisement (Month 21-completion)

Task 2. Collect pilot data on peripheral neurological (PN) effects in conjunction with serial neuropsychological and quality of life measures in women enrolled in a longitudinal study of cognitive effects of breast cancer treatment. (Months 1-18)
   1. Precepted Clinical Neurological Examination Skills (Cohen/Fadul) (Months 1-3)
   2. Precepted Neuropsychological Assessment Training (Ahles)
   3. Refine and produce standardized neuropathy assessment tool (Cohen/Fadul) (Month 1-5)
   4. Develop PN Data Management Procedures (Month 5)
   5. Attend weekly meetings of Psychooncology Center for Research and Breast Cancer Tumor Board to identify breast cancer patients on study (Months 6-18)
   6. Perform neuropathy assessment on breast cancer patients enrolled in Longitudinal Cognitive Effects (Months 6-18)

Task 3. Identify gaps in knowledge, research hypotheses, and feasible methods to study and develop interventions as a basis for a doctoral dissertation and future program of research (Months 6-24)
   1. Perform Review of Literature on Neurological Effects (Months 6-9)
   2. Perform Secondary analysis of existing data and summarize preliminary data (months 6-9)
   3. Develop draft of a model of neurological effects of breast cancer treatment (Month 10)
   4. Call expert panel meeting (Month 10 & 17)
   5. Incorporate expert panel comments into model (Month 11-12)
   6. Generate list of problems/hypotheses and methods to study, determine feasibility of conducting studies of above, determine funding sources, develop patient educational materials on CNS/PNS effects (Months 12-18)
   7. Develop dissertation defense based on above to prepare for qualifying exam (Months 12-18)
Revised Statement of Work (4/20/05 to completion 5/06)

This statement of work provides an overview of a two year project in which the candidate will spend half of her week on the Yale Campus and half on the Dartmouth Campus. A no-cost extension has been granted revising the statement of work to cover an additional year through 5/06).

Task 1. Develop research skills and abilities, including measurement, data analysis, and conceptual model development in breast cancer research through mentorship and doctoral education. (Months 1-18)

a. Weekly meeting with Dr. Ahles for mentored research supervision (Months 1-24)
b. Participate in 15 hrs/wk supervised Research Activities with doctoral faculty (Month 1-18)
c. Complete Year 1-Spring term (Months 1-5) and Year 2 –Fall and Spring (Months 9-17) required doctoral coursework (Yale)
d. Take Research Methods (CECS), Neurology, or Pharmacology Cognates (DMS) (Months 1-5, 9-12, 13-17)
e. Complete Preliminary Exam (at completion of 1st year of coursework) Month 6
f. Complete Qualifying Exam (at completion of 2nd year of coursework) Month 18
g. Dissertation underway (Month 21-completion)
h. Dissertation advisement (Month 21-completion)

Task 2. Collect pilot data on peripheral neurological (PN) effects in conjunction with serial neuropsychological and quality of life measures in women enrolled in a longitudinal study of cognitive effects of breast cancer treatment. (Months 1-18)

a. Precepted Clinical Neurological Examination Skills (Cohen/Fadul) (Months 1-3)
b. Precepted Neuropsychological Assessment Training (Ahles)
c. Revised: Incorporate FACT-TAXANE (neuropathy assessment) into Cognitive Studies (Months 10-26) and review preliminary data (Months 28-36)
d. Review literature on neuropathy assessment (Cohen/Fadul/Smith) (Month 12-18)
e. Evaluate CIPN measurement methods for use in dissertation proposal (Month 12-24)
f. Submit Abstracts (Month 18) on measurement methods and develop manuscript for publication (Month 18-27).
g. Develop PN Data Management Procedures (Month 5)
h. Attend weekly meetings of Psychooncology Center for Research and Breast Cancer Tumor Board to identify breast cancer patients on study (Months 6-18)
i. (Revised and incorporated this task into 2.c above) Perform neuropathy assessment on breast cancer patients enrolled in Longitudinal Cognitive Effects (Months 6-18)

Task 3. Identify gaps in knowledge, research hypotheses, and feasible methods to study and develop interventions as a basis for a doctoral dissertation and future program of research (Months 6-24 and extension Months 25-36)

a. Perform Review of Literature on Neurological Effects (Months 6-9)
b. Perform Secondary analysis of existing data and summarize preliminary data (months 6-9)
c. Develop draft of a model of neurological effects of breast cancer treatment (Month 10)
d. Call expert panel meeting (Month 10 & 17)
e. Incorporate expert panel comments into model (Month 11-12)
f. Generate list of problems/hypotheses and methods to study, determine feasibility of conducting studies of above, determine funding sources, develop patient educational materials on CNS/PNS effects (Months 12-18)
g. Develop dissertation defense based on above to prepare for qualifying exam (Months 12-18)
h. Perform on-going and final analysis of data from dissertation: (Months 25-36).
i. Dissertation defense: (proposed for Month 36).
MEASUREMENT ISSUES IN CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN)

Marie Bakitas, MS, ARNP, Ellen Smith, MSN, ARNP, Jeffrey A. Cohen, MD, Camilo Padul, MD

ABSTRACT

Purpose: To describe and compare measurement, feasibility, and utility of various objective and subjective measures of chemotherapy-induced peripheral neuropathy (CIPN) used in cancer clinical trials.

Background/Significance: CIPN is a common and serious complication of cancer chemotherapy that can cause significant functional and quality of life impairments. Although, other chemotherapy toxicities have been monitored or eliminated (e.g., nausea, neutropenia, and thrombocytopenia), CIPN remains a challenging problem. However, CIPN presents distinct and unmet needs, and the measures used to assess CIPN include self-report, observational, and objective methods.

Methods: A MEDLINE search of CIPN measures and clinical trials from 1990-2004 (Web citations) was conducted. Studies that evaluated CIPN using traditional clinical rating scales (e.g., Neuropathy Disability Index (NDI), clinically assessed) were included. Other evaluations included quality-of-life and symptom assessment outcome measures (QOLs), disease-specific scales, and devices to measure CIPN severity. The definitions and utility of various measurement tools were determined.

Results: Nineteen articles were included. Studies that evaluated CIPN using traditional clinical rating scales (e.g., NDI) were identified. Other evaluations included disease-specific scales, and devices to measure CIPN severity. The definitions and utility of various measurement tools were determined. In summary, the most common measures used to assess CIPN severity were the NDI and the pain subscale of the Brief Pain Inventory (BPI). Other common measures included the Neuropathy Impairment Score (NIS), the Neuropathy Disability Questionnaire (NDQ), and the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 2.0.

Conclusions: The results indicate that CIPN measurement tools are heterogeneous and may not be consistent across trials and are not considered a "gold standard." Additionally, inter- and intra-rater reliability and validity of some scales were established with substantial inter-rater reliability data. As a result, it is difficult to evaluate how well these measures capture the clinically relevant patient experience.

Implications: Use of CIPN measurement tools may be limited for routine use and understanding of potentially causative drug therapies. Measurement of symptom severity may reveal a lack of standardization and make future clinical trials assessing new agents difficult to compare.

METHOD

Literature review for two data sources included:
1. CIPN Measures: CIPN Measures
2. Chemotherapy Agents Reporting: Chemotherapy Agents Reporting

CIPN MEASURES: OBJECTIVE

Table 1: Objective Measures of CIPN

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDI</td>
<td>Neuropathy Disability Index</td>
<td>Bakitas et al. (2003)</td>
</tr>
<tr>
<td>BPI</td>
<td>Brief Pain Inventory</td>
<td>Sullivan et al. (1995)</td>
</tr>
<tr>
<td>NIS</td>
<td>Neuropathy Impairment Score</td>
<td>Hanks et al. (1999)</td>
</tr>
<tr>
<td>NDQ</td>
<td>Neuropathy Disability Questionnaire</td>
<td>Cohen et al. (2000)</td>
</tr>
</tbody>
</table>

CIPN MEASURES: SUBJECTIVE

Table 2: Subjective Measures of CIPN

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDI</td>
<td>Neuropathy Disability Index</td>
<td>Bakitas et al. (2003)</td>
</tr>
<tr>
<td>BPI</td>
<td>Brief Pain Inventory</td>
<td>Sullivan et al. (1995)</td>
</tr>
<tr>
<td>NIS</td>
<td>Neuropathy Impairment Score</td>
<td>Hanks et al. (1999)</td>
</tr>
<tr>
<td>NDQ</td>
<td>Neuropathy Disability Questionnaire</td>
<td>Cohen et al. (2000)</td>
</tr>
</tbody>
</table>

CONCLUSION

Based on a review of 45 clinical trials, we conclude:
1. CIPN incidence varies by study due to differences in drug, dose, patient, and psychological measures.
2. CIPN is often cited as a "dose-limiting toxic" but no standardized objective or subjective criteria exist to determine "clinically relevant" drug toxicity levels.
3. CIPN measures as described.
4. Studies were selected on a topic and following the following headings: Study author year Sample; Chemotherapy Drugs; Measures; CIPN Science/Results.
Appendix C.

Yale University Student Information System

Display Transcript

This is NOT an official transcript. A course for which a grade has not been submitted will appear separately under Courses in Progress. If your course displays with *** in the grade column, you must complete a course evaluation or indicate that you choose not to evaluate the course. Click on the link below the asterisks to go to the course evaluation page.

Transfer Credit  Institution Credit  Courses in Progress

Transcript Data
Registration ID: 1055427

***This is NOT an Official Transcript***

TRANSFER CREDIT ACCEPTED BY INSTITUTION

<table>
<thead>
<tr>
<th>Subject</th>
<th>Course</th>
<th>Title</th>
<th>Grade</th>
<th>Credit Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPRG</td>
<td>2003</td>
<td>Survey Research Methods</td>
<td>CR</td>
<td>3.30</td>
</tr>
</tbody>
</table>

Unofficial Transcript

<table>
<thead>
<tr>
<th>Subject</th>
<th>Course</th>
<th>Title</th>
<th>Grade</th>
<th>Credit Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPRG</td>
<td>2004</td>
<td>Health Policy 2</td>
<td>CR</td>
<td>3.30</td>
</tr>
</tbody>
</table>

INSTITUTION CREDIT

<table>
<thead>
<tr>
<th>Subject</th>
<th>Course</th>
<th>Title</th>
<th>Grade</th>
<th>Credit Hours</th>
<th>Grade Mode</th>
<th>Instructor</th>
</tr>
</thead>
<tbody>
<tr>
<td>NURS</td>
<td>529</td>
<td>Statistics for Clin Nurs Res</td>
<td>H</td>
<td>0.00</td>
<td>Nursing</td>
<td>M Funk</td>
</tr>
<tr>
<td>NURS</td>
<td>901</td>
<td>Methods for Nursing Research</td>
<td>H</td>
<td>3.00</td>
<td>Nursing</td>
<td>J Dixon</td>
</tr>
<tr>
<td>NURS</td>
<td>913</td>
<td>Conceptual Base for Hg Science</td>
<td>H</td>
<td>3.00</td>
<td>Nursing</td>
<td>C Gilless</td>
</tr>
<tr>
<td>NURS</td>
<td>915</td>
<td>Doc Research Pract</td>
<td>H</td>
<td>1.00</td>
<td>Nursing</td>
<td>R Mccorkle</td>
</tr>
<tr>
<td>NURS</td>
<td>943</td>
<td>Conceptual Basis for Fam Mgt</td>
<td>H</td>
<td>3.00</td>
<td>Nursing</td>
<td>G Mollard</td>
</tr>
</tbody>
</table>

Unofficial Transcript

Spring 2003

### Unofficial Transcript

#### Fall 2005

**College:** Nursing School  

<table>
<thead>
<tr>
<th>Subject</th>
<th>Course Title</th>
<th>Grade</th>
<th>Credit Hours</th>
<th>Instructor</th>
</tr>
</thead>
<tbody>
<tr>
<td>NURS</td>
<td>904 Neonatal Effectiveness Care Traint</td>
<td>H</td>
<td>3.00 Nursing</td>
<td>K. Knafl</td>
</tr>
<tr>
<td>NURS</td>
<td>915 Doctoral Research Pract I</td>
<td>H</td>
<td>1.00 Nursing</td>
<td>R. McCorflke</td>
</tr>
<tr>
<td>NURS</td>
<td>917 Adv Stats for Clin Nurs Rese</td>
<td>H</td>
<td>3.00 Nursing</td>
<td>G. Knafl</td>
</tr>
<tr>
<td>NURS</td>
<td>922 Multivariate Stat Model &amp; Buils</td>
<td>H</td>
<td>3.00 Nursing</td>
<td>M. Grey</td>
</tr>
</tbody>
</table>

#### Unofficial Transcript

#### Spring 2004

**College:** Nursing School  

<table>
<thead>
<tr>
<th>Subject</th>
<th>Course Title</th>
<th>Grade</th>
<th>Credit Hours</th>
<th>Instructor</th>
</tr>
</thead>
<tbody>
<tr>
<td>NURS</td>
<td>605 Cancer Pharmacology</td>
<td>HP</td>
<td>1.50 Nursing</td>
<td>C. Bemuthp</td>
</tr>
<tr>
<td>NURS</td>
<td>903 Measurement of Clin Variables</td>
<td>H</td>
<td>3.00 Nursing</td>
<td>J. Dixon</td>
</tr>
<tr>
<td>NURS</td>
<td>907 Dissertatin Seminar</td>
<td>YR</td>
<td>0.00 Nursing</td>
<td>R. McCorflke</td>
</tr>
<tr>
<td>NURS</td>
<td>915 Doctoral Research Pract II</td>
<td>RE</td>
<td>0.50 Nursing</td>
<td>R. McCorflke</td>
</tr>
<tr>
<td>NURS</td>
<td>925 Qualitative Research in Nurs</td>
<td>H</td>
<td>3.00 Nursing</td>
<td>K. Knafl</td>
</tr>
<tr>
<td>NURS</td>
<td>961 Htn Pol for Pub &amp; Prv Sects</td>
<td>HP</td>
<td>3.00 Nursing</td>
<td>S. Cohen</td>
</tr>
</tbody>
</table>

#### Unofficial Transcript

#### Summer 2004

**College:** Nursing School  

<table>
<thead>
<tr>
<th>Subject</th>
<th>Course Title</th>
<th>Grade</th>
<th>Credit Hours</th>
<th>Instructor</th>
</tr>
</thead>
<tbody>
<tr>
<td>NURS</td>
<td>991 Dissertatin Advancement</td>
<td>RE</td>
<td>2.00 Nursing</td>
<td>A. Szelenyi</td>
</tr>
</tbody>
</table>

#### Unofficial Transcript

#### Fall 2004

**College:** Nursing School  

<table>
<thead>
<tr>
<th>Subject</th>
<th>Course Title</th>
<th>Grade</th>
<th>Credit Hours</th>
<th>Instructor</th>
</tr>
</thead>
<tbody>
<tr>
<td>NURS</td>
<td>991 Dissertatin Advancement</td>
<td>RE</td>
<td>3.00 Nursing</td>
<td>K. Knafi</td>
</tr>
</tbody>
</table>

---

https://www1.sis.yale.edu/pls/banl/bwskotrn.P_ViewTran  

4/4/2005
COURSES IN PROGRESS

Spring 2005
College: Nursing School

<table>
<thead>
<tr>
<th>Subject</th>
<th>Course Title</th>
<th>Credit Hours</th>
<th>Grade Mode</th>
<th>Instructor</th>
</tr>
</thead>
<tbody>
<tr>
<td>NURS 961</td>
<td>Dissertation Advisement</td>
<td>3.00</td>
<td>Nursing</td>
<td>M. Knief</td>
</tr>
</tbody>
</table>

RELEASE: 5.5

Appendix D.

Neurological Effects of Cancer Tx Across Trajectory

Risk Factors
CNS/PNS
Trauma, DM
Genetic, ETCH
Menopause

Breast CA Diagnosis

Cure

Effects
CNS
Brain Mets
PNS
Lymphedema
Plexopathy

Breast CA Treatment
Surgery
XRT
Chemo
Hormonal

On-going Tx
Chemo
Hormones
XRT

Effects
CNS
Cognitive
PNS
Peripheral
Neuropathy
Pain

Palliative
Tx
Opioids
Steroids

Effects
CNS
Delerium
PNS
Neuropathy
Pain

Bakitas, 2003
Appendix E.

Proposed Model of CIPN Effects on QOL *

Physical Function
- ADL Dysfunction (rising from toilet)
- Hand Dysfunction (dressing, cooking, typing, writing, etc.)
- Foot Dysfunction (walking, driving, etc.)

Symptoms
- Tingling
- Burning/Pain
- Numbness
- Weakness
- Constipation
- CV effects (HR, BP)

Social
- Social Isolation
- Altered Role Function (work, home, leisure)

Psychological
- Anxiety
- Depression
- Fear
- Grief
- Body Image Disturbance
- Decision-making

CIPN Effects on HRQOL

*Based on cancer chemotherapy and DM literature

Bakitas 2003
Appendix F.

18. Bakitas Marie A.: Developing a Research Program on Neurological Effects of
Breast Cancer Treatment via Doctoral Education, in Department of Defense, Congressionally Directed Medical Research Programs: Http://cdmrp.army.mil/cgi-bin/search/search_results.pl, 2002


33. Bookbinder M: Nurse linkage agents efforts to facilitate the use of a research-based innovation, in Nursing. New York, New York: New York University, 1992


70. Colevas AD, Busse PM, Norris CM, et al. Induction chemotherapy with


Bakitas, Marie
DAMD-17-03-1-0298


125. Goodwin Pamela J., Black Jeanne T., Bordeleau Louise J., Ganz Patricia A. Health-related quality-of-life measurement in randomized clinical trials in breast cancer--


142. Hogan JW, Laird NM. Mixture models for the joint distribution of repeated
measures and event times. Statistics in Medicine 1997;16(239-257.
159. Knaf Kathleen, Howard MJ. Interpreting and reporting qualitative research. Research in Nursing and Health 1984;7(17-24)


216. Pearce IA, Cambray-Deakin MA, Burgoyne RD. Glutamate acting on NMDA receptors stimulates neurite outgrowth from cerebellar granule cells. FEBS Letter 1987;223(143-147).


232. Rose PG, Smrekar M. Improvement of paclitaxel-induced neuropathy by
245. Sandelowski Margarete, Davis Diane Holditch, Harris Betty Glenn. Artful design: Writing the proposal for research in the naturalist paradigm. Research in Nursing and Health 1989;12(77-84.
251. Schloerb PR, Skikne BS. Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. 23 1999;3(117-22)
274. Tashakkori Abbas, Teddlie Charles: Mixed methodology: Combining qualitative


310. Ziegler TR, Benefell K, Smith RJ, et al. Safety and metabolic effects of L-


**Who Do I Contact for More Information Or To Enroll In the Study?**

Provide your Oncologist or Nurse Practitioner with your name, phone number or email. Marie Bakitas will contact you or you may contact Marie Bakitas by phone or email.

---

**Who is Conducting This Study?**

**Marie Bakitas, MS, ARNP**
Nurse Practitioner  
Norris Cotton Cancer Center,  
Dartmouth-Hitchcock Medical Center

Doctoral Candidate  
Yale University School of Nursing

---

**Funded by:**
Department of Defense,  
Breast Cancer Research Program  
and  
American Cancer Society

---

**Contact the Study:**
Marie Bakitas, MS, ARNP  
Phone: 603-653-3524  
Email: marie.bakitas@dartmouth.edu

Dartmouth-Hitchcock Medical Center  
1 Medical Center Drive  
Lebanon, NH 03756

---

**DMS 0505**
**Understanding the Experience of Chemotherapy-Induced Peripheral Neuropathy**

**We need your help with a research study**

Do you have NUMBNESS, TINGLING, BURNING or PAIN in your FEET and/or HANDS from CANCER CHEMOTHERAPY?
Am I eligible?
If all of the statements below describe you, you may be eligible to participate in this study.

- If you have peripheral neuropathy caused by chemotherapy.
- Peripheral neuropathy feels like "pins and needles", burning, numbness, or tingling in the feet and/or hands.

- If you are receiving chemotherapy for any type of cancer.

- **Platinums**
  - cisplatin (Platinol)
  - carboplatin (Paraplatin)
  - oxaliplatin (Eloxatin)

- **Taxanes**
  - paclitaxel (Taxol)
  - docetaxel (Taxotere)

- **Plant Alkaloids**
  - vincristine (Oncovin)
  - vinblastine (Velban)
  - vinorelbine (Navelbine)

- **Other**
  - thalidomide (Thalidomide)
  - bortezomib (Velcade)

- If you did not have neuropathy before receiving chemotherapy.

- If you are 18 years of age or older.

What Is the Study About?
The purpose of the study is to understand what it is like to have the chemotherapy side effect called **peripheral neuropathy**.

What Will I Be Asked To Do?
We will ask you to participate in an interview and complete 2 questionnaires.

- In the interview a researcher will ask you to talk about your symptoms and how these may affect your everyday life.

- The two questionnaires will also ask about your symptoms.

The interview and questionnaires may take about an hour or longer. It will be done at a time and location that is convenient to you.

Why Is This Research Being Done?
This study will help doctors and nurses better understand the symptoms of peripheral neuropathy and how they can affect everyday life. When doctors and nurses understand these symptoms, they may be able to better recognize them. Better recognition may lead to improved treatment, comfort, and function during and after chemotherapy.